The New Technologies for Cervical Cancer screening 2 (NTCC2) clinical trial is amulticentric randomized trial comparing mRNA-HPV testing (by Aptima, Hologic) andp16/ki67 expression (dual-stain, by CINTec PLUS, Roche) to liquid-based cytology astriage for HPV-DNA-positive women attending cervical cancer screening. Here, MKI67 is linked to cervical carcinoma.